Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program

Highlights • HCV triple therapy delivered on-site at an opiate agonist treatment program. • SVR rates nearly equivalent to outcomes of patients treated in registration trials. • SVR rates equivalent to other real-world studies which did not enroll PWUDs. • There was no association between illicit dr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The International journal of drug policy 2015-10, Vol.26 (10), p.1014-1019
Hauptverfasser:	Litwin, Alain H, Soloway, Irene J, Cockerham-Colas, Lauren, Reynoso, Sheila, Heo, Moonseong, Tenore, Christopher, Roose, Robert J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Clinical outcomes Direct-acting antiviral agents Drug policy Drug therapy Drug Therapy, Combination Drug use Female HCV Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans IDU Injection drug users Injections Interferon-alpha - administration & dosage Interferon-alpha - therapeutic use Internal Medicine Male Medical Education Medical treatment Middle Aged Oligopeptides - administration & dosage Oligopeptides - therapeutic use Opiate Substitution Treatment - methods Polyethylene Glycols - administration & dosage Polyethylene Glycols - therapeutic use Proline - analogs & derivatives Proline - therapeutic use PWID PWUD Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Retrospective Studies Ribavirin - administration & dosage Ribavirin - therapeutic use Substance Abuse, Intravenous - complications Substance Abuse, Intravenous - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • HCV triple therapy delivered on-site at an opiate agonist treatment program. • SVR rates nearly equivalent to outcomes of patients treated in registration trials. • SVR rates equivalent to other real-world studies which did not enroll PWUDs. • There was no association between illicit drug use and SVR. • People who use drugs must have unrestricted access to direct-acting antiviral agents.
ISSN:	0955-3959 1873-4758
DOI:	10.1016/j.drugpo.2015.08.008